2025Q4
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Hertz Walter Marc | — | 385,510 | Apr 24, 2023 |
| Agro Albert | — | 172,189 | Apr 24, 2023 |
| Chaturvedi Vipin | — | 172,189 | Apr 24, 2023 |
| Kelly Leanne | CFO | 83,333 | Sep 26, 2023 |
| SALMON Pharma GmbH | 10% Owner | 47,063 | Feb 12, 2021 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2025 | Sep 22, 2025 | Kelly Leanne | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 18, 2025 | Sep 22, 2025 | Szekeres David Leslie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 18, 2025 | Sep 22, 2025 | Baker David Charles | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 18, 2025 | Sep 22, 2025 | SIMPSON CAMILLA V | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 18, 2025 | Sep 22, 2025 | Chaturvedi Vipin | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 18, 2025 | Sep 22, 2025 | Rongen Roelof | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 18, 2025 | Sep 22, 2025 | Hertz Walter Marc | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 27, 2025 | Hertz Walter Marc | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 27, 2025 | Szekeres David Leslie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 27, 2025 | Baker David Charles | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 27, 2025 | Rongen Roelof | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 27, 2025 | Chaturvedi Vipin | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 27, 2025 | SIMPSON CAMILLA V | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 27, 2025 | Kelly Leanne | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 13, 2025 | Aug 14, 2025 | SIMPSON CAMILLA V | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 13, 2025 | Aug 14, 2025 | Baker David Charles | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 13, 2025 | Aug 14, 2025 | Rongen Roelof | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 13, 2025 | Aug 14, 2025 | Szekeres David Leslie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2025 | Jan 24, 2025 | Kelly Leanne | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2025 | Jan 24, 2025 | Chaturvedi Vipin | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2025 | Jan 24, 2025 | Hertz Walter Marc | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2025 | Jan 24, 2025 | SIMPSON CAMILLA V | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2025 | Jan 24, 2025 | Baker David Charles | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2025 | Jan 24, 2025 | Szekeres David Leslie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 23, 2025 | Jan 24, 2025 | Rongen Roelof | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 22, 2023 | Sep 26, 2023 | Kelly Leanne | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 10, 2023 | Aug 14, 2023 | Szekeres David Leslie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 10, 2023 | Aug 14, 2023 | SIMPSON CAMILLA V | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 10, 2023 | Aug 14, 2023 | Rongen Roelof | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 10, 2023 | Aug 14, 2023 | Baker David Charles | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 25, 2023 | Chaturvedi Vipin | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 25, 2023 | SIMPSON CAMILLA V | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 25, 2023 | Agro Albert | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 25, 2023 | Rongen Roelof | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 25, 2023 | Hertz Walter Marc | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 21, 2023 | Apr 24, 2023 | Hertz Walter Marc | CEO | Neutral | 90.0 | +385,510 | 100.00% | ✗ | - |
| Apr 21, 2023 | Apr 24, 2023 | Agro Albert | Chief Medical Officer | Neutral | 90.0 | +172,189 | 100.00% | ✗ | - |
| Apr 21, 2023 | Apr 24, 2023 | Chaturvedi Vipin | Chief Scientific Officer | Neutral | 90.0 | +172,189 | 100.00% | ✗ | - |
| Apr 24, 2023 | Szekeres David Leslie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Dec 13, 2022 | Dec 15, 2022 | Thorell Marella | Director | Neutral | 27.5 | -28,517 | -75.00% | ✗ | - |
| Jul 1, 2022 | Jul 6, 2022 | Thorell Marella | Director | Neutral | 90.0 | +38,023 | 100.00% | ✗ | - |
| Jun 9, 2022 | Jun 10, 2022 | Ammer Richard | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 9, 2022 | Jun 10, 2022 | Payne Joseph E | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 9, 2022 | Jun 10, 2022 | Thorell Marella | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 23, 2022 | Mar 9, 2022 | Chhabra Meenu | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 9, 2022 | Chhabra Meenu | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 15, 2022 | Mar 1, 2022 | Baker David Charles | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 15, 2022 | Mar 1, 2022 | Kelly Leanne M. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 2, 2021 | Jun 4, 2021 | Kelly Leanne M. | CFO | Buy | 91.3 | +6,250 | 100.00% | ✗ | $25.2K |
| May 25, 2021 | May 27, 2021 | Payne Joseph E | Director | Buy | 82.5 | +17,500 | 2.07% | ✗ | $71.8K |
| May 14, 2021 | May 18, 2021 | Payne Joseph E | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 14, 2021 | May 18, 2021 | Ammer Richard | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 14, 2021 | May 18, 2021 | Levi Ofir | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 14, 2021 | May 18, 2021 | Kelly Leanne M. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 14, 2021 | May 18, 2021 | Toren Penny | SVP, Regul Affairs & Prog Mgmt | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 14, 2021 | May 18, 2021 | Baker David Charles | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 18, 2021 | Kelly Leanne M. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 12, 2021 | Feb 12, 2021 | Ammer Richard | Director | Buy | 97.5 | +47,063 | 100.00% | ✗ | $301.2K |
| Feb 12, 2021 | Feb 12, 2021 | SALMON Pharma GmbH | 10% Owner | Buy | 97.5 | +47,063 | 100.00% | ✗ | $301.2K |
| Feb 12, 2021 | Feb 12, 2021 | Thorell Marella | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 12, 2021 | Feb 12, 2021 | Baker David Charles | CEO | Buy | 95.0 | +8,843 | 100.00% | ✗ | $58.2K |
| Feb 10, 2021 | Payne Joseph E | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 9, 2021 | Thorell Marella | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 9, 2021 | Baker David Charles | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 9, 2021 | Levi Ofir | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 9, 2021 | Ammer Richard | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 9, 2021 | SALMON Pharma GmbH | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 9, 2021 | Toren Penny | SVP, Regul Affairs & Prog Mgmt | Neutral | 52.5 | - | 0.00% | ✗ | - |